Juniper Pharmaceuticals (JNP) vs. Neuralstem (CUR) Financial Comparison

Juniper Pharmaceuticals (NASDAQ: JNP) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.


This table compares Juniper Pharmaceuticals and Neuralstem’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juniper Pharmaceuticals 10.80% 17.32% 11.65%
Neuralstem -154,347.81% -148.94% -84.85%

Institutional and Insider Ownership

36.4% of Juniper Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Neuralstem shares are held by institutional investors. 11.6% of Juniper Pharmaceuticals shares are held by company insiders. Comparatively, 19.3% of Neuralstem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Juniper Pharmaceuticals and Neuralstem, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juniper Pharmaceuticals 0 1 2 0 2.67
Neuralstem 0 0 0 0 N/A

Juniper Pharmaceuticals currently has a consensus target price of $23.00, indicating a potential upside of 322.02%. Neuralstem has a consensus target price of $3.18, indicating a potential upside of 70.05%. Given Juniper Pharmaceuticals’ higher possible upside, analysts plainly believe Juniper Pharmaceuticals is more favorable than Neuralstem.

Earnings and Valuation

This table compares Juniper Pharmaceuticals and Neuralstem’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Juniper Pharmaceuticals $54.57 million 1.08 $5.95 million $0.59 9.24
Neuralstem $20,000.00 1,416.53 -$21.07 million ($1.66) -1.13

Juniper Pharmaceuticals has higher revenue and earnings than Neuralstem. Neuralstem is trading at a lower price-to-earnings ratio than Juniper Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Juniper Pharmaceuticals has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.


Juniper Pharmaceuticals beats Neuralstem on 10 of the 13 factors compared between the two stocks.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

About Neuralstem

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply